* INGEN BIOSCIENCES *
2001 - IDF
Chilly-Mazarin
(near Paris)
www.ingen.fr Design, Diagnostics
Key words: Serology, In-vitro, Biomarkers, Infectious diseases, Bacterial antigens, Microbiology, Non-invasive testing, Capucine, Abag
Mission: to design and manufacture protein biomarkers for multiparametric diagnostic in infectious diseases
Clients: Pharmaceutical industry
commercial@ingen.fr
Age: 8 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.-CEO: Hermet (Jean-Pierre) [born 1943, ex-Schering-Plough, Wyeth, Bentley, Peptide Immune Ligands (founder), Hybrigenics (founder), Hemosystem (founder)]
Sc.Dir.-CSO: Martin (Jacques) [Eng. ESITPA, ex-Clonatec, also Mktg.Dir]
Fin.Dir.-CFO: Zelaci (Elisabeth) [IAE]
BusDev:
Financers (Hist.): Innoven Partners, Société Générale A.M.
Note : Ingen website, acquired in 2006, updated with Ingen Biosciences (no company website ever as Abag) | Turnover (M€) : 0.05 (2008)
Total funding (M€) : 8.0
Last funding (M€) : 6.0
Focus : Infections
Position : Trade
Company confirm : neutral |
History | DATE | MILESTONE | TYPE | TIME | | 2009 .03 | Company rename as InGen Biosciences (from Abag) | ORGL | [7 years] |
| 2008 .12 | Nomination : Jean-Pierre Hermet, new CEO | ORGN | [7 years] |
| 2006 .07 | Acquisition of Ingen, a distribution company founded in 1993 | ACQ+ | [4 years] |
| 2006 .02 | 2nd round-financing : 6.0 M€, by new investor, Innoven (followed by Société Générale A.M.) | RFINB | [4 years] |
| 2003 .03 | 1st round-financing : 2.0 M€, by Société Générale A.M. | RFINA | [1 year] |
| 2001 .12 | Company founded by Marc Bourlioux and Jean-Louis Gaillard, as AbAg | ORGF | [0 year] | Actualisation / Updating: 14-Sept-2009 |
|
